Literature DB >> 9165033

Identification of a kinetically distinct activity of 11beta-hydroxysteroid dehydrogenase in rat Leydig cells.

R S Ge1, H B Gao, V L Nacharaju, G L Gunsalus, M P Hardy.   

Abstract

Leydig cells are susceptible to direct glucocorticoid-mediated inhibition of testosterone biosynthesis but can counteract the inhibition through 11beta-hydroxysteroid dehydrogenase (11beta-HSD), which oxidatively inactivates glucocorticoids. Of the two isoforms of 11beta-HSD that have been identified, type I is an NADP(H)-dependent oxidoreductase that is relatively insensitive to inhibition by end product and carbenoxolone (CBX). The type I form has been shown to be predominantly reductive in liver parenchymal cells and other tissues. In contrast, type II, which is postulated to confer specificity in mineralocorticoid receptor (MR)-mediated responses, acts as an NAD-dependent oxidase that is potently inhibited by both end product and CBX. The identity of the 11beta-HSD isoform in Leydig cells is uncertain, because the protein in this cell is recognized by an anti-type I 11beta-HSD antibody, but the activity is primarily oxidative, more closely resembling type II. The goal of the present study was to determine whether the kinetic properties of 11beta-HSD in Leydig cells are consistent with type I, type II, or neither. Leydig cells were purified from male Sprague-Dawley rats (250 g), and 11beta-HSD was evaluated in Leydig cells by measuring rates of oxidation and reduction, cofactor preference, and inhibition by end product and CBX. Leydig cells were assayed for type I and II 11beta-HSD and MR messenger RNAs (mRNAs), and for type I 11beta-HSD protein. Leydig cell 11beta-HSD had bidirectional catalytic activity that was NADP(H)-dependent. This is consistent with the hypothesis that type I 11beta-HSD is present in rat Leydig cells. However, unlike the type I 11beta-HSD in liver parenchymal cells, the Leydig cell 11beta-HSD was predominantly oxidative. Moreover, analysis of kinetics revealed two components, the first being low a Michaelis-Menten constant (Km) NADP-dependent oxidative activity with a Km of 41.5 +/- 9.3 nM and maximum velocity (Vmax) of 7.1 +/- 1.2 pmol x min x 10(6) cells. The second component consisted of high Km activities that were consistent with type I:NADP-dependent oxidative activity with Km of 5.87 +/- 0.46 microM and Vmax of 419 +/- 17 pmol x min x 10(6) cells, and NADPH-dependent reductive activity with Km of 0.892 +/- 0.051 microM and Vmax of 117 +/- 6 pmol x min x 10(6) cells. The results for end product and CBX inhibition were also inconsistent with a single kinetic activity in Leydig cells. Type I 11beta-HSD mRNA and protein were both present in Leydig cells, whereas type II mRNA was undetectable. We conclude that the low Km NADP-dependent oxidative activity of 11beta-HSD in Leydig cells does not confirm to the established characteristics of type I and may reside in a new form of this protein. We also demonstrated the presence of the mRNA for MR in Leydig cells, and the low Km component could allow for specificity in MR-mediated responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9165033     DOI: 10.1210/endo.138.6.5165

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  24 in total

Review 1.  Glucocorticoids, stress, and fertility.

Authors:  S Whirledge; J A Cidlowski
Journal:  Minerva Endocrinol       Date:  2010-06       Impact factor: 2.184

2.  The opposite roles of glucocorticoid and α1-adrenergic receptors in stress triggered apoptosis of rat Leydig cells.

Authors:  Silvana A Andric; Zvezdana Kojic; Maja M Bjelic; Aleksandar I Mihajlovic; Aleksandar Z Baburski; Srdjan J Sokanovic; Marija M Janjic; Natasa J Stojkov; Stanko S Stojilkovic; Tatjana S Kostic
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-11-13       Impact factor: 4.310

3.  Sequence and expression of 11beta-hydroxysteroid dehydrogenase type 1 cDNA cloned from pig testis.

Authors:  Shuji Ohno; Masanori Ohta; Yoko Honda; Shizuo Nakajin
Journal:  Mol Cell Biochem       Date:  2009-12-18       Impact factor: 3.396

4.  Evidence for expression of 11β-hydroxysteroid dehydrogenase type3 (HSD11B3/HSD11B1L) in neonatal pig testis.

Authors:  Shuji Ohno; Satomi Nakagawara; Yoko Honda; Shizuo Nakajin
Journal:  Mol Cell Biochem       Date:  2013-06-04       Impact factor: 3.396

5.  Characterization of 11β-hydroxysteroid dehydrogenase activities in the renal cell line LLC-PK(1) : Evidence for a third isoform?

Authors:  E Möbus; J J Rob Hermans; E Maser
Journal:  Endocrine       Date:  1999-12       Impact factor: 3.633

6.  Deficiency of CDKN1A or both CDKN1A and CDKN1B affects the pubertal development of mouse Leydig cells.

Authors:  Han Lin; Yadong Huang; Zhijian Su; Qiqi Zhu; Yufei Ge; Guimin Wang; Claire Q F Wang; Motoko Mukai; Denise R Holsberger; Paul S Cooke; Qing-Quan Lian; Ren-Shan Ge
Journal:  Biol Reprod       Date:  2015-01-21       Impact factor: 4.285

7.  7alpha-hydroxytestosterone affects 1 beta-hydroxysteroid dehydrogenase 1 direction in rat Leydig cells.

Authors:  Guo-Xin Hu; Qing-Quan Lian; Bing-Bing Chen; Pramod V Prasad; Narender Kumar; Zhi-Qiang Zheng; Ren-Shan Ge
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

Review 8.  Rapid mechanisms of glucocorticoid signaling in the Leydig cell.

Authors:  Guo-Xin Hu; Qing-Quan Lian; Han Lin; Syed A Latif; David J Morris; Matthew P Hardy; Ren-Shan Ge
Journal:  Steroids       Date:  2007-12-28       Impact factor: 2.668

9.  Hexose-6-phosphate dehydrogenase and 11beta-hydroxysteroid dehydrogenase-1 tissue distribution in the rat.

Authors:  Elise P Gomez-Sanchez; Damian G Romero; Angela F de Rodriguez; Mary P Warden; Zygmunt Krozowski; Celso E Gomez-Sanchez
Journal:  Endocrinology       Date:  2007-11-26       Impact factor: 4.736

10.  In utero exposure to di-(2-ethylhexyl) phthalate decreases mineralocorticoid receptor expression in the adult testis.

Authors:  D B Martinez-Arguelles; M Culty; B R Zirkin; V Papadopoulos
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.